Latest Commercialisation News

Nexsen Limited (ASX:NXN) reported a 30% rise in net loss to $6.55 million for FY26, driven by ongoing investment in its Group B Streptococcus rapid diagnostic and Asia-Pacific growth initiatives following its October 2025 IPO.

Singular Health Group lifted revenues over fivefold to $1.43 million in FY26, driven by US commercial rollouts of its 3DICOM platform, but posted a $6.34 million loss. The company strengthened its US foothold with FDA clearance and a controlling stake in an associate.

Vectus Biosystems has reported a striking turnaround with a $1.56 million profit for the 2026 financial year, reversing a prior year loss and improving its balance sheet significantly.

Provaris Energy reported a $4.045 million loss for FY2026 as it progressed proprietary hydrogen and liquid CO₂ storage technologies, expanded strategic partnerships, and boosted cash reserves through multiple placements.

PYC Therapeutics strengthened its financial footing with a $600 million capital raise and made notable clinical progress across four RNA therapeutic programs targeting genetic diseases.

Cambium Bio has secured FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development costs and timelines. Despite a AUD 4.1 million loss for FY2026, the company strengthened its funding position and manufacturing partnerships ahead of patient dosing targeted for late 2026.

Orcoda Limited reported a 26% reduction in net loss and a 23% rise in Annual Recurring Revenue, boosted by a new $8 million per annum multi-year contract with Wagner Corporation, setting the stage for SaaS expansion in FY27.

Papyrus Australia has expanded its TBS contract for an additional sample run after mixed trial results and secured a $200,000 unsecured loan with Irwin Biotech, advancing its capital raising efforts with L39 Capital.

OncoSil Medical lifted revenues 44% in FY26 to $1.68 million and trimmed losses by 28% to $10.86 million, buoyed by key regulatory approvals including FDA HDE and Australian TGA listings. The company is poised for commercial launches in the US and Australia, with strong clinical data underpinning its growth.

HITIQ Limited posted a 21% drop in revenue to $1.59 million and reduced its net loss by 15% to $6.1 million for FY26, advancing commercialisation of its concussion management platform PROTEQT™ despite ongoing funding pressures and regulatory hurdles.

4DMedical’s CT:VQ™ lung imaging technology secured FDA clearance and CMS reimbursement, driving rapid adoption in top US medical centres and expanding its addressable market to $3 billion with new clinical programs and European contracts.

Memphasys has secured early Thai FDA approval for its Felix™ System, triggering a three-year exclusive distribution deal with IVF Envimed and prompting additional orders amid strong clinic interest.